Health Care/Hospital
Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
* Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment * Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by func...
2026-07-13 16:53
2678
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI),and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical ...
2026-07-13 08:30
3735
Smartee S22: Incorporating GS MART Technology into Occlusal Reconstructive Therapy in Prosthodontics
SHENZHEN, China, July 10, 2026 /PRNewswire/ -- Smartee Denti-Technology has announced the launch of S22: GS MART (Mandibular Repositioning Technology) for Occlusal Reconstruction in Prosthodontic Dentistry, expanding the clinical application of its GS MART into prosthodontic dentistry. The projec...
2026-07-10 18:07
5217
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of adva...
2026-07-10 16:53
4949
POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare
GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disea...
2026-07-09 20:00
5144
Professor Gang Shen's Orthodontic Team Publishes Third Consecutive Paper in the Journal of Aligner Orthodontics
SHANGHAI, July 8, 2026 /PRNewswire/ -- Professor Gang Shen, Chief GS R&D Scientist of Smartee Denti-Technology and Chief Orthodontist at Taikang Dental, together with his orthodontic team, has published a new researcharticle titled " Pathological Mandibular Retrusion: Causality and Orthodontic Int...
2026-07-09 17:55
4179
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective...
2026-07-09 17:28
4464
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PL...
2026-07-09 15:31
4402
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 8, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study,was published online in full in The New England Journal o...
2026-07-09 10:16
3413
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden th...
2026-07-09 09:13
3536
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The s...
2026-07-09 08:30
3975
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO , July 8, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, theBIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACRO...
2026-07-09 00:00
3205
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company...
2026-07-08 22:17
3234
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
* First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. * Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from development through commercialization. HA...
2026-07-08 22:00
3572
Seegene Launches Industry's First Global Million Clinical Study to Shape New Disease-Specific Testing Standards
* Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. * The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-...
2026-07-08 21:00
3800
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
* Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) * Included in the MSCI ESG Selection Indexes for the fourth consecutive year * Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Bi...
2026-07-08 15:15
5715
OTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology Therapies
SHANGHAI, July 7, 2026 /PRNewswire/ -- OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today announced that it has entered into a strategic collaboration agreement with LG Chem, a leading global company ...
2026-07-08 07:00
2715
Bambu Lab Announces 48-Hour Charity Fundraiser to Support Venezuela Earthquake Relief
AUSTIN, Texas, July 7, 2026 /PRNewswire/ -- Building on the ongoing relief efforts of Bambu Lab LATAM, including a USD 50,000 contribution toward earthquake recovery in Venezuela, Bambu Lab today announced a further step: a 48-hour community initiative beginning July 13 at 8:00 a.m. UTC−4, 2026. ...
2026-07-08 00:00
3228
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine * Rentosertib represents a novel mec...
2026-07-07 21:43
4942
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capab...
2026-07-07 20:50
4666
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 297 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 291 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 277 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
11815
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
8444
Carro secures strategic investment from Orico
2026-09-18 16:29
7805
